Lixte announces results of collab with Netherlands Cancer Institute

LIXTE Biotechnology announced that a recently posted article in BioRxiv based on the results of a collaboration between the Company and the Netherlands Cancer Institute, shows that inhibition of PP2A in colon cancer cells, using LIXTE’s lead clinical compound LB-100, leads to major changes in the way cancer cells process their mRNAs. Based on this finding, cancer cells are predicted to produce a significant number of aberrant proteins that can be recognized by the immune system. This newly discovered mechanism, by which LB-100 turns immunologically “cold” tumors “hot,” adds to several additional mechanisms that have recently been described through which LB-100 sensitizes cancer cells to immune checkpoint blockade. John Kovach, M.D., CEO and Founder of LIXTE, said, “The case for combining LB-100 with immunotherapy is based on extensive pre-clinical data. The new findings provide a clear mechanistic underpinning for why this synergy is being seen. This data further supports our focus on developing LB-100 in combination with checkpoint blockade antibodies and strengthens our expectation that our current and upcoming clinical trials combining LB-100 with immune checkpoint blockade will be effective in treating cancer.”